ARSB and melanoma: Decline in ARSB leads to reduced binding of galectin-3 with C4S and increased availability of galectin-3 for nuclear translocation and cooperation with AP-1 and Sp1 in promoter activation, for expression of genes such as Wnt9A in colonic epithelium [32], versican in prostate cells [27], and CSPG4 in melanoma [33].